Statins Reduce the Effectiveness of Rituximab in Treating B Cell Lymphomas
Author Information
Author(s): Winiarska Magdalena, Bil Jacek, Wilczek Ewa, Wilczynski Grzegorz M, Lekka Malgorzata, Engelberts Patrick J, Mackus Wendy J. M, Gorska Elzbieta, Bojarski Lukasz, Stoklosa Tomasz, Nowis Dominika, Kurzaj Zuzanna, Makowski Marcin, Glodkowska Eliza, Issat Tadeusz, Mrowka Piotr, Lasek Witold, Dabrowska-Iwanicka Anna, Basak Grzegorz W, Wasik Maria, Warzocha Krzysztof, Sinski Maciej, Gaciong Zbigniew, Jakobisiak Marek, Parren Paul W. H. I, Golab Jakub
Primary Institution: Medical University of Warsaw
Hypothesis
Do statins impair the effectiveness of rituximab in killing B cell lymphomas?
Conclusion
Statins significantly decrease the effectiveness of rituximab by altering the conformation of CD20 on B cell lymphomas.
Supporting Evidence
- Statins were found to significantly decrease rituximab-mediated complement-dependent cytotoxicity.
- Short-term atorvastatin treatment in patients led to reduced anti-CD20 binding.
- Cholesterol depletion impaired the binding of anti-CD20 antibodies to lymphoma cells.
Takeaway
Statins, which lower cholesterol, can make a cancer treatment called rituximab less effective by changing how a protein on cancer cells looks.
Methodology
The study used various assays to measure the effects of statins on rituximab-mediated cytotoxicity in B cell lymphoma cells.
Potential Biases
Potential bias due to the small number of patients and the specific conditions under which the study was conducted.
Limitations
The study was limited to a small sample size and focused on specific statins.
Participant Demographics
Five patients with hypercholesterolemia, otherwise healthy.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website